JP2023522415A5 - - Google Patents

Info

Publication number
JP2023522415A5
JP2023522415A5 JP2022564300A JP2022564300A JP2023522415A5 JP 2023522415 A5 JP2023522415 A5 JP 2023522415A5 JP 2022564300 A JP2022564300 A JP 2022564300A JP 2022564300 A JP2022564300 A JP 2022564300A JP 2023522415 A5 JP2023522415 A5 JP 2023522415A5
Authority
JP
Japan
Prior art keywords
azd9833
cancer
administered
product according
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522415A (ja
JP7712955B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/060589 external-priority patent/WO2021214253A1/en
Publication of JP2023522415A publication Critical patent/JP2023522415A/ja
Publication of JP2023522415A5 publication Critical patent/JP2023522415A5/ja
Application granted granted Critical
Publication of JP7712955B2 publication Critical patent/JP7712955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564300A 2020-04-24 2021-04-22 癌の治療のための投薬レジメン Active JP7712955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014914P 2020-04-24 2020-04-24
US63/014,914 2020-04-24
PCT/EP2021/060589 WO2021214253A1 (en) 2020-04-24 2021-04-22 Dosage regimen for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2023522415A JP2023522415A (ja) 2023-05-30
JP2023522415A5 true JP2023522415A5 (cg-RX-API-DMAC7.html) 2024-04-26
JP7712955B2 JP7712955B2 (ja) 2025-07-24

Family

ID=75728802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564300A Active JP7712955B2 (ja) 2020-04-24 2021-04-22 癌の治療のための投薬レジメン

Country Status (12)

Country Link
US (3) US20210330653A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138834A1 (cg-RX-API-DMAC7.html)
JP (1) JP7712955B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005269A (cg-RX-API-DMAC7.html)
CN (2) CN115443135A (cg-RX-API-DMAC7.html)
AU (1) AU2021260829B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021141A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179907A1 (cg-RX-API-DMAC7.html)
IL (1) IL297216A (cg-RX-API-DMAC7.html)
MX (1) MX2022013391A (cg-RX-API-DMAC7.html)
TW (1) TWI918645B (cg-RX-API-DMAC7.html)
WO (1) WO2021214253A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024083716A1 (en) * 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
KR102898494B1 (ko) * 2023-10-04 2025-12-09 삼성전자주식회사 양자점 조성물, 그 제조방법, 그의 경화물, 및 이를 포함하는 표시장치
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1863810A4 (en) 2005-03-22 2010-03-31 Astrazeneca Ab NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
EP3312184A4 (en) 2015-06-16 2019-02-27 Jiangsu Hengrui Medicine Co., Ltd. PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
JP6920295B2 (ja) 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
EP3378861B1 (en) 2015-11-12 2021-08-04 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
WO2017107754A1 (zh) 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3440067B1 (en) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
JP6793836B2 (ja) 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体idh1およびidh2阻害剤としての7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物
AR110782A1 (es) 2017-01-30 2019-05-02 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa

Similar Documents

Publication Publication Date Title
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2024133475A5 (cg-RX-API-DMAC7.html)
CN114641293A (zh) 一种fgfr抑制剂的用途
JP2022531898A5 (cg-RX-API-DMAC7.html)
JP2014515373A5 (cg-RX-API-DMAC7.html)
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
JP2022509262A5 (cg-RX-API-DMAC7.html)
JP2012522837A5 (cg-RX-API-DMAC7.html)
TW202333675A (zh) 用於治療癌症之組合療法之用途
Ventafridda et al. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs
JP2024527023A5 (cg-RX-API-DMAC7.html)
JP2019508476A5 (cg-RX-API-DMAC7.html)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2024517085A5 (cg-RX-API-DMAC7.html)
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2024539476A5 (cg-RX-API-DMAC7.html)
Kooybaran et al. Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib
JP2012525358A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2025511401A5 (cg-RX-API-DMAC7.html)
JP2004525143A5 (cg-RX-API-DMAC7.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用